Recent agreements between the Trump administration and 16 major pharmaceutical companies have led to substantial price reductions on numerous high-cost drugs, making some of the lowest prices available to American patients.

Launched on February 5, 2026, TrumpRx.gov provides patients with coupons for discounts aligning U.S. prices with the lowest rates in other developed nations under most-favored-nation policies. The site initially covers drugs from AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer, with more added ongoing. Patients can access these savings for cash payments or through manufacturer channels.

Notable reductions include Ozempic dropping from $1,028 to an average of $350 or as low as $199 per month, Wegovy injectable from $1,349 to as low as $199, and its pill form to $149. Eli Lilly's Zepbound fell from $1,088 to $346 average or $299 low. Insulin Lispro reached $25 per month, while fertility drugs like Gonal-F dropped to $168 per pen from higher prior costs. These changes stem from executive actions starting in 2025, including 16 deals announced since September.

The deals commit companies to Medicaid discounts, equal launch prices across wealthy nations, and cash-pay reductions via TrumpRx. Early 2026 saw big commercial cuts, such as 75% off Fiasp insulin and 37% to 44% reductions on Farxiga, Jardiance, and Eliquis.

Complementing these efforts, Medicare's first negotiated prices took effect January 1, 2026, for 10 high-cost drugs without generics. Discounts range from 38% to 79% off 2023 list prices, projecting $6 billion in Medicare savings and $1.5 billion in out-of-pocket costs annually. Affected drugs include Eliquis, Jardiance, Xarelto, Januvia, and others used by millions of seniors.

While some companies raised list prices on 872 brand-name drugs by a median 4% in early 2026, the targeted cuts on popular medications have provided relief. These developments follow years of criticism over high U.S. drug costs compared to abroad, with the administration touting the lowest prices ever for affected patients.